CFAP70: A Potential Drug Target and Biomarker (G118491)

Target Name: CFAP70

NCBI ID: G118491

CFAP70

CFAP70: A Potential Drug Target and Biomarker

Chondroitin sulfate proteoglycans (CSGs) are a type of extracellular matrix (ECM) component that is involved in various physiological processes in the body, including tissue repair, inflammation, and cell-cell adhesion. One of the most well-known CSGs is chondroitin sulfate (CS) itself, which is a glycosaminoglycan (GAG) that is found in various tissues, including tendons, ligaments, and brain. Another well-known CSG is hyaluronic acid (HA), which is also a GAG found in various tissues, including skin, heart, and artificially-derived matrices.

Recent studies have identified CFAP70, a protein that is expressed in various tissues and is involved in the regulation of cell adhesion, as a potential drug target and biomarker. CFAP70 is a 70-kDa protein that is composed of two main subunits, alpha- and beta-subunits. The alpha-subunit is responsible for the catalytic activity of CFAP70, while the beta-subunit is involved in the regulation of CFAP70's activity.

CFAP70 is involved in the regulation of cell adhesion by modulating the interactions between adhesion molecules and the cytoskeleton. Adhesion molecules are proteins that are involved in cell-cell adhesion, including cadherins, which are transmembrane proteins that are involved in cell-cell adhesion, and tight junctions, which are involved in the regulation of ion and solute transport across the cell membrane. CFAP70 is known to regulate the interactions between these adhesion molecules and the cytoskeleton by modulating the cytoskeleton and the cytosolic environment.

One of the key functions of CFAP70 is its role in the regulation of cell adhesion. CFAP70 has been shown to play a role in the regulation of adhesion molecule interactions by modulating the cytoskeleton and the cytosolic environment. For example, studies have shown that CFAP70 can regulate the trafficking of adhesion molecules to the cell surface by modulating the activity of the cytoskeleton. Additionally, CFAP70 has been shown to regulate the cytoskeleton by modulating the level of microtubules in the cytosol.

CFAP70 is also involved in the regulation of cell signaling by modulating the activity of various signaling pathways. For example, CFAP70 has been shown to play a role in the regulation of the TGF-beta signaling pathway, which is involved in cell growth, differentiation, and inflammation. Additionally, CFAP70 has been shown to regulate the activity of the PI3K/Akt signaling pathway, which is involved in the regulation of cell signaling.

CFAP70 has also been shown to have potential as a biomarker for various diseases, including cancer. For example, studies have shown that CFAP70 is overexpressed in various cancer tissues, including breast, ovarian, and prostate cancer. Additionally, studies have shown that CFAP70 is involved in the regulation of cancer cell growth and metastasis.

In conclusion, CFAP70 is a protein that is involved in the regulation of cell adhesion and signaling by modulating the cytoskeleton and the cytosolic environment. Its role in these processes makes it a potential drug target and biomarker for various diseases, including cancer. Further research is needed to fully understand the mechanisms of CFAP70's role in these processes and its potential as a drug.

Protein Name: Cilia And Flagella Associated Protein 70

Functions: Axoneme-binding protein that plays a role in the regulation of ciliary motility and cilium length

The "CFAP70 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CFAP70 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets